Immediate Impact
15 standout
Citing Papers
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Works of Eric Zhi being referenced
390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial
2023
Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Eric Zhi | 55 | 23 | 43 | 43 | 13 | 83 | |
| Lena Wagner | 63 | 31 | 100 | 19 | 14 | 170 | |
| Karin H. Herbschleb | 74 | 15 | 120 | 44 | 10 | 164 | |
| Danielle Croucher | 46 | 10 | 44 | 24 | 15 | 96 | |
| Bruno Chiurazzi | 49 | 24 | 31 | 11 | 12 | 113 | |
| Qinqin Liu | 93 | 38 | 46 | 15 | 14 | 204 | |
| Michael Pearlman | 35 | 12 | 31 | 23 | 9 | 110 | |
| Megan H. Jagosky | 61 | 14 | 51 | 38 | 11 | 108 | |
| Klaus Kirchbacher | 47 | 49 | 35 | 35 | 10 | 101 | |
| Dominik Karres | 43 | 7 | 18 | 28 | 13 | 108 | |
| Mohan K. Tummala | 48 | 17 | 85 | 50 | 16 | 168 |
All Works
Loading papers...